Drugs / CFT8919
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06641609 | Dec 2024 → Dec 2025 overdue | non-small cell lung carcinoma | Betta Pharmaceuticals Co., Ltd. | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CFT8919 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06641609 ↗ |
| Route | Oral | “Take CFT8919 capsules at different doses.” NCT06641609 ↗ |